NCT03967977 2026-01-26
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
BeOne Medicines
Phase 3 Recruiting
Clinical Trials
9 trialsNCT07296705 2025-12-22
HARBOR
Fujian Medical University Union Hospital
Phase 2 Recruiting
NCT07233252 2025-11-18
Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer
Tianjin Medical University Second Hospital
Phase 2 Recruiting
NCT06916494 2025-04-10
Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer
First Affiliated Hospital of Chongqing Medical University
Phase 1 Recruiting
NCT05531123 2024-07-12
Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer
Fudan University
Phase 2 Recruiting
NCT06441110 2024-06-04
Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer
Fujian Medical University Union Hospital
Phase 3 Recruiting
NCT06387056 2024-04-26
SEGNO
The First Affiliated Hospital of Xiamen University
Phase 2 Recruiting
NCT06211790 2024-01-18
Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma
Fudan University
Phase 2 Recruiting
NCT05957757 2023-08-31
RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression
RenJi Hospital
Phase 2 Recruiting